非酒精性脂肪性肝病合并2型糖尿病患者的临床特征及危险因素分析

Abstract
Figure/Table
References (30)
Related Citation (15)

Download: PDF (687 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the clinical characteristics and risk factors of nonalcoholic fatty liver disease (NAFLD) patients with type 2 diabetes mellitus (T2DM). Methods The clinical data of 349 NAFLD patients admitted to the First Affiliated Hospital of Xinjiang Medical University from August 2020 to August 2021 were retrospectively analyzed. According to the presence or absence of T2DM, the patients were divided into a simple NAFLD group (281 cases) and a NAFLD combined T2DM group (68 cases). The clinical data were collected to analyze the risk factors of NAFLD developing T2DM. Results The age, family history of diabetes, fasting blood glucose, and glycosylated hemoglobin in the NAFLD combined with T2DM group were higher than those in the simple NAFLD group, while the high-density lipoprotein was lower than that in the simple NAFLD group, and the differences were statistically significant (P ＜ 0.05). Spearson correlation analysis showed that NAFLD complicated with T2DM was positively correlated with age, fasting blood glucose, and glycosylated hemoglobin (r ＞ 0, P ＜ 0.05); it was negatively correlated with high-density lipoprotein (r ＜ 0, P ＜ 0.05). Logistic regression analysis showed that age (OR = 1.037), fasting blood glucose (OR = 1.420), high-density lipoprotein (OR = 0.301), and glycosylated hemoglobin (OR = 1.186) were independent risk factors for T2DM in NAFLD (P ＜ 0.05). Receiver operating characteristic curve analysis showed that fasting blood glucose, glycosylated hemoglobin, and high-density lipoprotein had diagnostic value for NAFLD-induced T2DM (P < 0.05). Conclusion Age, fasting blood glucose, high-density lipoprotein, and glycosylated hemoglobin were independent risk factors for NAFLD to develop T2DM.

Key words： Nonalcoholic fatty liver disease Type 2 diabetes mellitus High density lipoprotein Risk factors

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	MA Hailin QUAN Li JIANG Sheng

Cite this article:

MA Hailin QUAN Li JIANG Sheng. Analysis of clinical characteristics and risk factors in patients with nonalcoholic fatty liver disease complicated with type 2 diabetes mellitus[J]. 中国医药导报, 2022, 19(21): 70-73,82.

URL:

https://www.yiyaodaobao.com.cn/EN/ OR https://www.yiyaodaobao.com.cn/EN/Y2022/V19/I21/70

[1] Younossi ZM，Koenig AB，Abdelatif D，et al. Global epidemiology of fatty liver disease-meta analytic assessment of prevalence，incidence and outcomes [J]. Hepatology，2016，64（1）：73-84.
[2] 周烨威，王继海，赵红，等.活血降脂方治疗非酒精性脂肪肝的CT定量疗效评价[J].现代中西医结合杂志，2018， 27（9）：975-977.
[3] 黄樱硕，董瑞华，尤红.非酒精性脂肪性肝炎新药临床试验的难度与挑战[J].临床肝胆病杂志，2021，37（8）：1948-1952.
[4] 高鑫，王杉杉.重视非酒精性脂肪肝和2型糖尿病的关系研究[J].中华肝脏病杂志，2014，22（3）：161-164.
[5] 梁玲霞，赵猛，姚佳丽，等.2型糖尿病并发非酒精性脂肪肝患者的临床特征及影响因素分析[J].老年医学研究，2021，2（2）：1-5.
[6] Fernando B，Kenneth C. Management of nonalcoholic fatty liver disease in patients with type 2 diabetes：a cell to action [J]. Diabetes Care，2017，40（3）：419-430.
[7] 杨永刚，李庆杰，张泽鹏，等.基于网络药理学肝脂溶颗粒治疗2型糖尿病合并脂肪肝的分子机制[J].中国老年学杂志，2020，12（40）：5266-5270.
[8] 中华医学会糖尿病学分会.中国2型糖尿病防治指南（2017年版）[J].中华糖尿病杂志，2018，10（1）：64-67.
[9] 施军平，范建高.中国脂肪性肝病诊疗规范化的专家建议（2019年修订版）[J].中华肝脏病杂志，2019，27（10）：748-753.
[10] Williams CD，Stengel J，Asike MI，et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy：a prospective study [J]. Gastroenterol，2011，140（1）：124-131.
[11] Kim D，Touros A，Kim WR. Nonalcoholic fatty liver disease and metabolic syndrome [J]. Clin Liver Dis，2018， 22（1）：133-140.
[12] Li J，Zou B，Yeo YH，et al. Prevalence，incidence，and outcome of non-alcoholic fatty liver disease in Asia，1999-2019：a systematic review and meta-analysis [J]. Lancet Gastroenterol Hepatol，2019，4（5）：389-398.
[13] Zhou F，Zhou JH，Wang WX，et al. Unexpected rapid increase in the burden of NAFLD in China from 2008 to 2018：a systematic review and meta-analysis [J]. Hepatology，2019，70（4）：1119-1133.
[14] Kumar R，Priyadarshi RN，Anand U. Non-alcoholic fatty liver disease：growing burden，adverse outcomes and associations [J]. J Clin Transl Hepatol，2020，8（1）：76-86.
[15] 王林，刘学恩，庄辉.非酒精性脂肪性肝病组学生物标志物的研究进展[J].中华肝脏病杂志，2021，29（6）：604-608.
[16] Anstee QM，Targher G，Day CP. Progression of NAFLD to diabetes mellitus，cardiovascular disease or cirrhosis [J]. Nat Rev Gastroenterol Hepatol，2013，10（6）：330-344.
[17] 周雨，张智伟，王京奇.从“二次打击”学说探讨中药防治非酒精性脂肪肝的研究进展[J].中医药导报，2017， 23（18）：109-111.
[18] Smith BW，Adams LA. Nonalcoholic fatty liver disease and diabetes mellitus：pathogenesis and treatment [J]. Nature Rev Endocrinol，2011，7（8）：456-465.
[19] Deguise MO，Baranello G，Mastella C，et al. Abnormal fatty acid metabolism is a core component of spinal muscular atrophy [J]. Ann Clin Transl Neurol，2019，6（8）：1519-1532.
[20] 唐东旭，黄钟鸣，栾雨婷，等.非酒精性脂肪肝患者合并2型糖尿病的危险因素分析[J].中国现代医生，2020， 58（6）：26-29.
[21] 张梵子，王洪东，毕艳，等.超重和肥胖患者血清泌乳素水平与非酒精性脂肪性肝病的关系[J].中华糖尿病杂志，2018，10（3）：7-10.
[22] 辛晟梁，徐可树.非酒精性脂肪性肝病发病机制新认识[J].临床肝胆病杂志，2017，33（8）：1581-1583.
[23] 王百灵，刘静，张琦，等.2型糖尿病伴非酒精性脂肪肝与血尿酸水平和胰岛素抵抗的关系研究[J].中国基层医药，2018，25（3）：273-276.
[24] 关润年，陈璐，苏虹，等.非酒精性脂肪肝合并T2DM患者血清IGF-1、IGF-2水平与胰岛素抵抗的相关性分析[J].中外医学研究，2020，18（19）：61-63.
[25] 孙妍，王露.卡格列净联合二甲双胍对2型糖尿病合并非酒精性脂肪肝患者血尿酸及胰岛素抵抗的影响[J].中国医学创新，2021，18（30）：121-124.
[26] 阎利萍，左吉卉，吴明江，等.脂肪酸代谢与非酒精性脂肪肝疾病关系的研究进展[J].中国医药科学，2020，10（20）：35-39，56.
[27] Bae JC，Suh S，Park SE，et al. Regular exercise is associated with a reduction in the risk of NAFLD and decreased liver enzymes in individuals with NAFLD independent of obesity in Korean adults [J]. PLoS One，2012，7（10）：e46819.
[28] 牛茼，王婉，李天天，等.妊娠期糖尿病和/或非酒精性脂肪肝代谢相关因素分析及TyG指数在妊娠期对代谢疾病的诊断价值[J].中国医药导报，2020，17（12）：97-100，108.
[29] 杨高中，孙夏林，杨生晟，等.二甲双胍辅助治疗非酒精性脂肪肝的临床效果[J].中国当代医药，2020，27（2）：25-27.
[30] 延华，张粉利，徐邦强，等.老年2型糖尿病合并非酒精性脂肪肝患者的危险因素分析[J].中国临床保健杂志，2018，21（1）：33-35.